The Lancet Commission on Schizophrenia and Psychotic Disorders
Choose your language
The Lancet Commission on Schizophrenia and Psychotic Disorders

Reassessing schizophrenia and psychotic disorders for a new era of care.

The Lancet Commission is an international, interdisciplinary effort synthesising the highest-quality evidence on psychosis, and translating it into clinically useful, mechanistically grounded, and socially relevant guidance for the decade ahead.

Florence kick-off held on 27 March 2026

The first paper announcing the Lancet Commission on Schizophrenia and Psychotic Disorders.

Read the paper announcing the Lancet Commission →

Why this Lancet Commission matters

Among the most disabling and conceptually challenging conditions in global health.

Current diagnostic categories remain clinically useful, but they do not fully capture the marked biological, clinical, prognostic, and etiological heterogeneity of psychotic syndromes. The Lancet Commission delivers a critical, integrative, and forward-looking reassessment of the field, including transdiagnostic interfaces and implications for diagnosis, treatment, and public policy.

1

Set a forward-looking research roadmap

Going beyond a traditional literature review to identify innovative, high-priority research directions for the next decade of psychosis science.

2

Challenge outdated assumptions

Identifying where evidence is weak, contradictory, or where current categories no longer serve patients or science.

3

Advance a mechanistic understanding

Moving toward a more biologically grounded, clinically useful, and socially relevant view of psychotic disorders.

4

Generate actionable recommendations

For clinicians, researchers, policymakers, and, centrally, people with lived experience and their families.

Roadmap

A two-year timeline, from kick-off to submission.

Eight quarters of coordinated work across nine working groups, culminating in submission of the Lancet Commission paper in early 2028. The schedule below is tentative and may evolve as work progresses.

Indicative timeline, subject to change.

  1. Fundraising for the Commission’s organisation

  2. Priority-setting completed

    Completed
  3. Expert selection and written input completed

    Completed
  4. First full working-group drafts

  5. First integrated Commission draft

  6. SIRS meeting, Montréal, Canada

  7. Second integrated draft

  8. Final internal review

  9. Submission of the main paper

Structure

Nine interrelated working groups, one integrated narrative.

Each working group is led by a Core Expert and developed with invited experts and junior scientists, harmonised into a single Lancet Commission framework.

01Working Group

Concept, boundaries, and validity

Re-examining the conceptual basis of schizophrenia and the boundaries of psychotic syndromes.

Peter Falkai (Germany)Group leads
Joanna Moussiopoulou (Germany)Junior researcher
José Rubio (USA)
Laila Asmal (Africa)
Sherry Chan (China)
Stefan Leucht (Germany)
Georg Schomerus (Germany)

Contributing experts

Selected reading

Schizophrenia: An overview

McCutcheon et al., JAMA Psychiatry (2020)

02Working Group

Life course, staging, and progression

From early risk states through chronic illness, staging models and trajectories of psychosis.

Alison Yung (Australia)Group leads
Carl Moller (Australia)Junior researcher
Monica Calkins (USA)
Pablo Gaspar (Chile)
Celso Arango (Spain)
Dan Siskind (Australia)

Contributing experts

Selected reading

The clinical staging model in psychosis

Shah et al., Schizophrenia Bulletin (2025)

03Working Group

Epidemiology, risk factors, and cost

Population-level burden, modifiable risk, and the economic footprint of psychotic disorders.

Maxime Taquet (UK)Group leads
Sophie Shang (UK)Junior researcher
James Kirkbride (UK)
Mary Cannon (Ireland)
Crick Lund (Africa)

Contributing experts

Selected reading

Social determinants of mental disorders and the Sustainable Development Goals

Lund et al., The Lancet Psychiatry (2018)

04Working Group

Pathophysiology and biomarkers

Synthesizing mechanistic evidence and the state of biomarkers for diagnosis and stratification.

Robert McCutcheon (UK)Group leads
Max Doody (UK)Junior researcher
Carol Tamminga (USA)
Bita Moghaddam (Iran/USA)
Oliver Howes (UK)
John Torous (USA)

Contributing experts

Selected reading

Research Domain Criteria: Toward a new classification framework

Insel et al., American Journal of Psychiatry (2010)

05Working Group

Psychiatric and somatic comorbidities

Physical health, multimorbidity, and the complex interface with other psychiatric conditions.

Dan Siskind (Australia)Group leads
Sean Halstead (Australia)Junior researcher
Toby Pillinger (UK)
Najma Siddiqi (Pakistan/USA)
Brian O’Donoghue (Ireland)
Alison Yung (Australia)
Robert McCutcheon (UK)

Contributing experts

Selected reading

Prevalence of multimorbidity in people with and without severe mental illness

Halstead et al., The Lancet Psychiatry (2024)

06Working Group

Public understanding and stigma

Stigma, discrimination, and how societies respond to people with psychotic illness.

Nicola Reavley (Australia)Group leads
Anna Ross (Australia)Junior researcher
Claire Henderson (UK)
Georg Schomerus (Germany)
Celine Zimmerer (Germany)

Contributing experts

Selected reading

The Lancet Commission on ending stigma and discrimination in mental health

Thornicroft et al., The Lancet (2022)

07Working Group

Therapeutic strategies and interventions

Pharmacological, psychosocial, and emerging therapies, what works, for whom, and when.

Mark Weiser (Israel)Group leads
Mohammed Aboukaoud (Israel)Junior researcher
Deanna Kelly (USA)
Josh Kantrowitz (USA)
Alkomiet Hasan (Ireland)

Contributing experts

08Working Group

Clinical and public policy recommendations

Translating evidence into actionable clinical and public policy guidance worldwide.

Marion Leboyer (France) & Michael Berk (Australia)Group leads
Bruno Agustini (Brazil/Australia)Junior researcher
Lukoye Atwoli (Kenya)
Tianmei Si (China)
John Torous (USA)
Nicola Reavley (Australia)
Crick Lund (Africa)

Contributing experts

09Working Group

Research perspectives and future directions

Setting the agenda, open questions, methods, and priorities for the next decade of research.

Andreas Meyer-Lindenberg (Germany)Group leads
Dilsa Altinok (Germany)Junior researcher
Dost OngĂĽr (USA)
Kerstin Brennand (USA)
Stefan Leucht (Germany)

Contributing experts

Selected reading

Toward principles of brain network organization and function

Kulkarni & Bassett, Annual Review of Biophysics (2025)

How working groups are developed

A coherent process, from expert input to integrated narrative.

Invited experts feed key references into working group teams of core experts and junior scientists, who draft, revise, and align each working group to a shared Lancet Commission framework.

01

Expert input

Invited experts contribute key references and specialist perspectives to each working group.

02

Drafting and revision

Teams of core experts and junior scientists draft, discuss, and revise the working group.

03

Alignment

Each working group is aligned to a shared Lancet Commission framework and integrated into one narrative.

Have your say

Suggest a research topic

Anyone can suggest research priorities for schizophrenia and psychotic disorders. Age, sex and language are optional and help us understand who is contributing.

Submissions are anonymous; an approximate country code may be saved from your IP.

Questions or details

Prefer to get in touch directly?

For questions about the Lancet Commission, partnerships, or media inquiries, email us at eve.freitas@fondation-fondamental.org.